Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-5491|32|7|981-982

ISSN： 0742-3071

Source： DIABETIC MEDICINE, Vol.32, Iss.7, 2015-07, pp. : 981-982

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?

By  

Nephron Clin Pract, Vol. 118, Iss. 4, 2011-02 ,pp. : c380-c383

Karger

Access to resources Recommend Favorite

Growing Evidence Showing Association of Chronic Kidney Disease and Coronary Artery Disease Should Impact Clinical Practice

By  

Cardiology, Vol. 120, Iss. 4, 2012-01 ,pp. : 209-210

Karger

Access to resources Recommend Favorite

Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 3, 2012-08 ,pp. : 187-196

Bentham Science Publishers

Access to resources Recommend Favorite

Should We Continue to Use the Cockcroft-Gault Formula?

By  

Nephron Clin Pract, Vol. 116, Iss. 3, 2010-07 ,pp. : c172-c186

Karger

Access to resources Recommend Favorite

Implementing an evidence‐based clinical decision support tool to improve the detection, evaluation, and referral patterns of adult chronic kidney disease patients in primary care

By  

JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS (ELECTRONIC), Vol. 29, Iss. 12, 2017-12 ,pp. : 741-753

John Wiley & Sons Inc

Access to resources Recommend Favorite